Other news

Eight IBUB researchers among the 2% worldwide more influential researchers

A recent article published in PLOS Biology, presents a list of the 2% of scientists worldwide that lead different disciplines. This ranking has been conducted with the information provided by the Scopus database. Eight IBUB researchers (J. Argilés, X. Barril, J. Garcia-Fernández, R. Lavilla, F.J. Luque, D. Muñoz-Torrero, M. Rosés and  F. Villarroya), are among

Computational biology to improve drug design – Ramon Margalef Prize

The Ramon Margalef Prize, awarded by the Board of Trustees, has been given to a study in the field of computational biology. Specifically, the award has been given to Sergio Ruiz, for his work on an alternative and more efficient method to design drugs. This is a new way to identify molecules that are a

A study analyses the risk genetic factors shared between ADHD and disruptive behaviour disorders

People with attention-deficit / hyperactivity disorder (ADHD) combined with disruptive behaviour disorders (DBDs) share about the 80% of genetic variants associated with aggressive and antisocial behaviours. This is one of the conclusions of a study published in the journal Nature Communications which counts on the participation of professor Bru Cormand, from the Faculty of Biology and the

Described a mechanism that inhibits tumor-associated macrophage immunosupressive activity

Tumor cells are able to avoid the attack of the immune system through several mechanisms. For instance, these can secrete factors that turn macrophages –cells in the immune system– into dual action agents that contribute to the tumor progress and will protect it from immune body defences: these become, thus, the tumor-associated macrophages (TAMs). An

The MPET Lab (IBUB) participates in an ambitious consortium to design drugs to enhance the immune response against cancer

The project will develop new compounds against three therapeutic targets linked to tumor inflammation and will study their combined use to improve immunotherapies. The initiative has been funding with more than 2.5 million euros and is part of a Retos Colaboración call. The Molecular Pharmacology and Experimental Therapeutics (MPET) research group, led by Marçal Pastor-Anglada,

La Marató 2019: IBUB’s science supports the fight against rare diseases

La Marató de TV3 and Catalunya Ràdio will give 14.053.915€ to a total of 41 research projects focused on the study of rare diseases. In the 2019 edition, a total of 228 projects were submitted, and were assessed according to its quality, methodology and relevance by 190 internationally distinguished experts on the issue. He management

Sant Joan de Déu Research Institute recognized as CERCA center

The Sant Joan de Déu Research Institute (IRSJD), which counts on the participation of the University of Barcelona, has been recognized by the board of trustees of the Institution for Research Centers in Catalonia (CERCA) as a CERCA centre. This award involves the development of a frontier research aimed at the scientific and economic impact

IBUB study identifies new functions in the gene that causes Machado-Joseph disease

Ataxia is a minority disease with genetic origins, known for its neuromuscular alterations due to the selective loss of neurons in the cerebellum, the organ of our nervous systems which controls movement and balance. UB researchers have identified new functions in the ataxin 3 gene (ATXN3) –which causes Machado-Joseph disease, the most common type of

TRAF7 syndrome, a rare disease. Experts of the Human Molecular Genetics Group of the UB identify 45 patients with a rare disease

One of the main limitations to study rare diseases is finding enough affected people. Regarding the TRAF7 syndrome, a rare disease and defined in a recent study by the Human Molecular Genetics Group of the University of Barcelona, the starting point was the identification of the Patient Zero affected by an undescribed de novo mutation in scientific

IBUB team to expand frontiers of multicomponent reaction-based molecular synthesis

The synthesis of complex molecules such as drugs, requires a process that sometimes involves several phases that increase its cost and harden the access to the product. Now, a team of the UB has designed a new methodological approach that combines multicomponent reactions with domino type processes –continuous transformations on an only compound– to ease